Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Unknown 1Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 55Decitabine 33Azacitidine 30Idarubicin 22venetoclax 21fludarabine 16Cyclophosphamide 16Granulocyte Colony-Stimulating Factor 15Daunorubicin 12Mitoxantrone 9Etoposide 8Cladribine 8Busulfan 8Aclarubicin 8Homoharringtonine 7Filgrastim 7Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5aclacinomycins 4Tretinoin 4Sorafenib 4Radiotherapy 4Polymerase Chain Reaction 4Mycophenolic Acid 4Lenalidomide 4Gemtuzumab 4Cyclosporine 4Clofarabine 4Arsenic Trioxide 4sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myeloid, Acute × IL32 protein, human × Clear all
NCT02809092 2019-10-15

Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia

Hospital de Clinicas de Porto Alegre

Phase 1/2 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡